RxDoctor Payments Data

Anna Lark, PA

Physician Assistant · Myrtle Beach, SCNPI 1508646688

Payments from drug & device makers

$2,359in general payments, 2019–2025

Across 138 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$370
  • GSK$221
  • AstraZeneca$210
  • Abbott$195
  • AbbVie$195
  • Pfizer$188
  • plus $980 from 26 others

What the payments were for

  • Food & beverage$2,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,359 in reported general payments places this provider in the 80th percentile of 1,852 physician assistant providers in South Carolina.

See all physician assistant providers in South Carolina

Medicare billing

Part B allowed, 2024
$28,643
Medicare patients
152
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$26,821
JardianceEmpagliflozin18$14,362
EliquisApixaban12$8,641
Albuterol Sulfate HfaAlbuterol Sulfate30$699
Fluticasone Propionate37$581
Famotidine19$535
Atorvastatin Calcium40$497
Trazodone Hcl39$477
Valsartan24$433
Gabapentin43$369
Losartan Potassium46$349
Omeprazole29$335
Rosuvastatin Calcium42$265
Doxycycline Hyclate33$254
Duloxetine Hcl16$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$150$26,82121 claims
Boehringer IngelheimJardiance$18$14,36218 claims
PfizerEliquis$188$8,64112 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$16634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,852 physician assistant providers in South Carolina.

Other physician assistant in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →